|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3536373839404142434445...6768» |
- Enrollment change: Coagulation Changes in Trauma Patients (clinicaltrials.gov) - May 4, 2014
P=N/A, N=40, Completed, Sponsor: University of Miami
N=200 --> 40
- Trial completion: Coagulation Changes in Trauma Patients (clinicaltrials.gov) - May 4, 2014
P=N/A, N=40, Completed, Sponsor: University of Miami
N=200 --> 40 Recruiting --> Completed
- | mycophenolate mofetil / Generic mfg.
Trial completion: Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - May 4, 2014
P2, N=20, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- Arzerra (ofatumumab) / Novartis, Genmab
Trial termination: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - May 4, 2014
P2, N=3, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; funding was withdrawn
- Darzalex (daratumumab) / J&J
Enrollment open: A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 4, 2014
P1, N=12, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Terminated; funding was withdrawn Not yet recruiting --> Recruiting
- prednisone / Generic mfg., lenalidomide / Generic mfg.
Trial completion date, Combination therapy: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (clinicaltrials.gov) - May 1, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Mar 2012 --> Dec 2010
- Clinical: Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=74, Recruiting, Sponsor: Case Comprehensive Cancer Center
- Rituxan (rituximab) / Roche
Trial primary completion date: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Apr 30, 2014
P2, N=4, Terminated, Sponsor: Weill Medical College of Cornell University
Trial completion date: Mar 2012 --> Dec 2010 Trial primary completion date: Jun 2015 --> Oct 2013
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 30, 2014
P2, N=36, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2015 --> Oct 2013 Trial primary completion date: Feb 2016 --> Nov 2013
- Rituxan (rituximab) / Roche
Trial completion date: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Apr 30, 2014
P2, N=4, Terminated, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Feb 2016 --> Nov 2013 Trial completion date: Jun 2016 --> Apr 2014
- Rituxan (rituximab) / Roche
Trial termination: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Apr 30, 2014
P2, N=4, Terminated, Sponsor: Weill Medical College of Cornell University
Trial completion date: Jun 2016 --> Apr 2014 Recruiting --> Terminated; Slow Accrual
- Rituxan (rituximab) / Roche
Enrollment change: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Apr 30, 2014
P2, N=4, Terminated, Sponsor: Weill Medical College of Cornell University
Recruiting --> Terminated; Slow Accrual N=23 --> 4
- |||||| Abstilla (lonoctocog alfa) / CSL Behring
Enrollment open: Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A (clinicaltrials.gov) - Apr 30, 2014
P3, N=75, Recruiting, Sponsor: CSL Behring
N=23 --> 4 Not yet recruiting --> Recruiting
- |||| bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment open: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 30, 2014
P1/2, N=69, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Trial completion, Tumor cell: Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Apr 30, 2014
P1/2, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion: Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Apr 30, 2014
P2, N=36, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || gandotinib (LY 2784544) / Eli Lilly
Trial primary completion date: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Apr 29, 2014
P1, N=80, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Apr 2014
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Apr 29, 2014
P3, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- || Trial initiation date: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Apr 28, 2014
P=N/A, N=300, Not yet recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Initiation date: Apr 2014 --> Jul 2014
- MK-2206 / Merck (MSD)
Enrollment change: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Apr 27, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2014 --> Jul 2014 N=96 --> 45
- | Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Trial initiation date: PERSEPT 1: Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors (clinicaltrials.gov) - Apr 24, 2014
P3, N=25, Recruiting, Sponsor: rEVO Biologics
N=96 --> 45 Initiation date: Jan 2014 --> Apr 2014
- | Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Enrollment open: PERSEPT 1: Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors (clinicaltrials.gov) - Apr 24, 2014
P3, N=25, Recruiting, Sponsor: rEVO Biologics
Initiation date: Jan 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- || Combination therapy: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 23, 2014
P1/2, N=259, Active, not recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Apr 2011
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
New P2 trial: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Apr 22, 2014
P2, N=20, Not yet recruiting, Sponsor: Galena Biopharma, Inc.
- | balixafortide (POL 6326) / Spexis
Enrollment change: Exploratory Study on POL6326 in Stem Cell Mobilization (clinicaltrials.gov) - Apr 21, 2014
P2a, N=21, Completed, Sponsor: Polyphor Ltd.
Trial primary completion date: Sep 2014 --> Apr 2011 N=36 --> 21
- Mozobil (plerixafor) / Sanofi
Enrollment closed, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - Apr 21, 2014
P4, N=57, Active, not recruiting, Sponsor: University of Florida
N=36 --> 21 Recruiting --> Active, not recruiting
- | balixafortide (POL 6326) / Spexis
Trial completion: Exploratory Study on POL6326 in Stem Cell Mobilization (clinicaltrials.gov) - Apr 21, 2014
P2a, N=21, Completed, Sponsor: Polyphor Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- dinaciclib (MK-7965) / Merck (MSD)
Trial completion date: Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2014
P2, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment closed: Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2014
P2, N=16, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Active, not recruiting
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment change: Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=15 --> 29
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment closed: Viral Kinetics in HCV Clearance in Subjects With Hemophilia (clinicaltrials.gov) - Apr 21, 2014
P4, N=20, Active, not recruiting, Sponsor: Kenneth Sherman
N=15 --> 29 Recruiting --> Active, not recruiting
- ||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2014
P3, N=351, Completed, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders (clinicaltrials.gov) - Apr 20, 2014
P2, N=125, Recruiting, Sponsor: Gilead Sciences
- |||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 17, 2014
P2, N=194, Completed, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cyclosporine ophthalmic emulsion / Generic mfg.
Enrollment change: Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder (clinicaltrials.gov) - Apr 16, 2014
P3, N=165, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed N=256 --> 165
- | cyclosporine ophthalmic emulsion / Generic mfg.
Enrollment closed: Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder (clinicaltrials.gov) - Apr 16, 2014
P3, N=165, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=256 --> 165 Recruiting --> Active, not recruiting
- | Enrollment change: Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Apr 15, 2014
P3, N=72, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=206 --> 72
- | Darzalex (daratumumab) / J&J
New P1 trial: A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 15, 2014
P1, N=12, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Post-transplantation: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- | PAT-SM6 / Patrys
Trial completion: Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2014
P1, N=12, Completed, Sponsor: Patrys Ltd.
N=206 --> 72 Recruiting --> Completed
- || hydrocortisone / Generic mfg.
New P3 trial: Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock (clinicaltrials.gov) - Apr 13, 2014
P3, N=240, Completed, Sponsor: Nanjing PLA General Hospital
- Zelboraf (vemurafenib) / Roche
New P2 trial: A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib (clinicaltrials.gov) - Apr 13, 2014
P2, N=41, Not yet recruiting, Sponsor: University of Arkansas
- bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: RENVEL: Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure (clinicaltrials.gov) - Apr 13, 2014
P2, N=60, Completed, Sponsor: PETHEMA Foundation
Recruiting --> Completed Recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (clinicaltrials.gov) - Apr 13, 2014
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Willfact (human von Willebrand factor) / LFB Biotechnologies
Trial initiation date: Willebrand International Non-interventional Global Surveillance (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=80, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Mar 2014
- Willfact (human von Willebrand factor) / LFB Biotechnologies
Enrollment open: Willebrand International Non-interventional Global Surveillance (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=80, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Initiation date: Oct 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- |||| Xyntha (moroctocog alfa) / Pfizer
Enrollment open, P4 data: Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A (clinicaltrials.gov) - Apr 10, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Clinical: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma (clinicaltrials.gov) - Apr 10, 2014
P2, N=75, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- DCR-MYC / Novo Nordisk
New P1 trial, Metastases: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Apr 8, 2014
P1, N=66, Recruiting, Sponsor: Dicerna Pharmaceuticals, Inc.
- || Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial completion: Extension Study of Biostate in Subjects With Von Willebrand Disease (clinicaltrials.gov) - Apr 7, 2014
P3, N=20, Completed, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Active, not recruiting --> Completed